These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28934596)

  • 1. Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension.
    Zamanian RT; Hedlin H; Greuenwald P; Wilson DM; Segal JI; Jorden M; Kudelko K; Liu J; Hsi A; Rupp A; Sweatt AJ; Tuder R; Berry GJ; Rabinovitch M; Doyle RL; de Jesus Perez V; Kawut SM
    Am J Respir Crit Care Med; 2018 Mar; 197(6):788-800. PubMed ID: 28934596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Differences and Outcomes between Methamphetamine-associated and Idiopathic Pulmonary Arterial Hypertension in the Pulmonary Hypertension Association Registry.
    Kolaitis NA; Zamanian RT; de Jesus Perez VA; Badesch DB; Benza RL; Burger CD; Chakinala MM; Elwing JM; Feldman J; Lammi MR; Mathai SC; McConnell JW; Presberg KW; Robinson JC; Sager J; Shlobin OA; Simon MA; Kawut SM; Glidden DV; Singer JP; De Marco T;
    Ann Am Thorac Soc; 2021 Apr; 18(4):613-622. PubMed ID: 33064950
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival.
    Sajan I; Manlhiot C; Reyes J; McCrindle BW; Humpl T; Friedberg MK
    Am Heart J; 2011 Sep; 162(3):562-8. PubMed ID: 21884877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
    Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
    Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methamphetamine and the risk of pulmonary arterial hypertension.
    Ramirez RL; Perez VJ; Zamanian RT
    Curr Opin Pulm Med; 2018 Sep; 24(5):416-424. PubMed ID: 30036313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics and Outcome of Methamphetamine-Associated Pulmonary Arterial Hypertension and Dilated Cardiomyopathy.
    Zhao SX; Kwong C; Swaminathan A; Gohil A; Crawford MH
    JACC Heart Fail; 2018 Mar; 6(3):209-218. PubMed ID: 29496022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
    Chung L; Liu J; Parsons L; Hassoun PM; McGoon M; Badesch DB; Miller DP; Nicolls MR; Zamanian RT
    Chest; 2010 Dec; 138(6):1383-94. PubMed ID: 20507945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?
    Chin KM; Channick RN; Rubin LJ
    Chest; 2006 Dec; 130(6):1657-63. PubMed ID: 17166979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension.
    Sadeghi S; Granton JT; Akhavan P; Pasarikovski CR; Roos AM; Thenganatt J; Moric J; Johnson SR
    Respirology; 2015 Apr; 20(3):481-7. PubMed ID: 25583377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry.
    Chung L; Farber HW; Benza R; Miller DP; Parsons L; Hassoun PM; McGoon M; Nicolls MR; Zamanian RT
    Chest; 2014 Dec; 146(6):1494-1504. PubMed ID: 24992469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).
    Barst RJ; Ivy DD; Foreman AJ; McGoon MD; Rosenzweig EB
    Am J Cardiol; 2014 Jan; 113(1):147-55. PubMed ID: 24176071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.
    Girgis RE; Mathai SC; Krishnan JA; Wigley FM; Hassoun PM
    J Heart Lung Transplant; 2005 Oct; 24(10):1626-31. PubMed ID: 16210140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank).
    Charoenpong P; Dhillon N; Murnane K; Goeders N; Hall N; Keller C; Bhuiyan MAN; Walter R
    BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38061804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
    Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of pulmonary arterial hypertension in connective tissue disease.
    Grünig E
    Drugs; 2012 May; 72(8):1039-56. PubMed ID: 22621693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung Function, Inflammation, and Endothelin-1 in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension.
    Low A; George S; Howard L; Bell N; Millar A; Tulloh RMR
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29444773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.
    Lettieri CJ; Nathan SD; Barnett SD; Ahmad S; Shorr AF
    Chest; 2006 Mar; 129(3):746-52. PubMed ID: 16537877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension.
    Ross DJ; Hough G; Hama S; Aboulhosn J; Belperio JA; Saggar R; Van Lenten BJ; Ardehali A; Eghbali M; Reddy S; Fogelman AM; Navab M
    Pulm Circ; 2015 Dec; 5(4):640-8. PubMed ID: 26697171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.